Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082

Rizzo et al. (1) report some remarkable differences in mean absolute glucose excursions (MAGE), markers of oxidative stress, and markers of inflammation in a randomized, open-label trial of sitagliptin 100 mg once daily versus vildagliptin 50 mg twice daily. MAGE is a measure of large glycemic swings, taking into account only …